coronaviru
diseas
spread
rapidli
throughout
globe
associ
signific
mortal
particularli
atrisk
group
poor
prognost
featur
hospit
admiss
spectrum
diseas
broad
among
hospitalis
patient
pneumonia
sepsi
respiratori
failur
acut
respiratori
distress
syndrom
ard
frequent
encount
complic
pathophysiolog
sever
acut
respiratori
syndrom
cor
ona
viru
induc
ard
similar
sever
communityacquir
pneumonia
caus
virus
bacteria
overproduct
earli
respons
proinflammatori
cytokin
tumour
necrosi
factor
tnf
result
describ
cytokin
storm
lead
increas
risk
vascular
hyperperm
multiorgan
failur
eventu
death
high
cytokin
concentr
unab
time
therefor
therapeut
strategi
investig
target
overact
cytokin
respons
anticytokin
therapi
immunomodul
must
balanc
maintain
adequ
inflammatori
respons
pathogen
clearanc
activ
coagul
pathway
immun
respons
infect
result
overproduct
proinflammatori
cytokin
lead
multiorgan
injuri
although
main
function
thrombin
promot
clot
format
activ
platelet
convert
fibrinogen
fibrin
thrombin
also
exert
multipl
cellular
effect
augment
inflamm
via
proteinaseactiv
receptor
par
princip
thrombin
gener
tightli
control
neg
feedback
loop
physiolog
anticoagul
antithrombin
iii
tissu
factor
pathway
inhibitor
protein
c
system
inflamm
three
control
mechan
impair
reduc
anti
coagul
concentr
due
reduc
product
increas
consumpt
defect
pro
coagulantanticoagul
balanc
predispos
develop
microthrombosi
dissemin
intra
vascular
coagul
multiorgan
failureevidenc
sever
pneumonia
rais
ddimer
concentr
poor
prognost
featur
dissemin
intravascular
coagul
common
nonsurvivor
find
increas
ddimer
level
patient
prompt
question
regard
coexist
venou
thromboembol
exacerb
ventilationperfus
mismatch
studi
shown
pulmonari
emboli
preval
howev
due
increas
risk
bleed
despond
relat
previou
neg
trial
endogen
anticoagul
sepsi
clinician
might
reluct
offer
outsid
prevent
manag
venou
thrombo
embol
clear
effect
coagul
activ
go
beyond
clot
crosstalk
coagul
inflamm
significantli
affect
diseas
progress
lead
poor
outcom
prophylact
dose
low
molecular
weight
heparin
lmwh
recommend
hospitalis
patient
prevent
venou
thromboembol
treatment
dose
lmwh
contempl
significantli
rais
ddimer
concentr
due
concern
thrombi
pulmonari
circul
lmwh
also
antiinflammatori
properti
might
benefici
context
therefor
paramount
look
role
par
antagonist
coagul
proteas
inhibitor
main
thrombin
receptor
mediat
thrombininduc
platelet
aggreg
well
interplay
coagul
inflammatori
fibrot
respons
import
aspect
pathophysiolog
fibroprolif
lung
diseas
seen
although
less
like
effect
venou
thromboembol
antagonist
develop
antiplatelet
drug
treatment
cardiovascular
diseas
might
potenti
attenu
deleteri
effect
associ
activ
coagul
cascad
thrombin
format
clinic
approv
antagonist
shown
reduc
level
proinflammatori
cytokin
neutrophil
lung
inflamm
alveolar
leak
bacteri
pneumonia
lipopolysaccharideinduc
lung
injuri
murin
model
moreov
role
host
immun
virus
investig
one
studi
protect
myocard
coxacki
viru
decreas
influenza
viral
load
murin
lung
anoth
studi
activ
follow
influenza
challeng
associ
deleteri
inflamm
worsen
surviv
suggest
initi
activ
requir
host
control
viru
load
left
unab
inflamm
result
reduc
surviv
halflif
vorapaxar
might
consid
prolong
context
manag
acut
ill
especi
without
known
revers
agent
antiplatelet
effect
associ
bleed
risk
howev
import
note
clinic
trial
vorapaxar
particip
receiv
aspirin
thienopyridin
enrol
antagonist
eg
never
progress
clinic
trial
short
halfliv
could
revisit
antithrombin
antifactor
xa
direct
oral
anticoagul
well
establish
prevent
manag
venou
thromboembol
sinc
thrombin
main
activ
coagul
factor
xa
induc
product
proinflammatori
cytokin
via
activ
drug
might
promis
amelior
diseas
progress
sever
bleed
risk
alway
concern
procoagul
state
benefit
might
outweigh
risk
revers
drug
anticoagul
effect
inhibitor
exist
target
thrombin
coagul
factor
xa
might
therefor
attract
approach
reduc
microthrombosi
lung
injuri
associ
poor
outcom
declar
compet
interest
ricardo
j
jose
ari
manuel
rjose
rbhtnhsuk
